EXAS – exact sciences corporation (US:NASDAQ)

News

Abivax Announces Former Prometheus COO, Mark Stenhouse, Appointed as Board Observer & Advisor to Abivax [Yahoo! Finance]
Exact Sciences Unveils Data Showing Promise of Multi-Cancer Early Detection at AACR Special Conference on Liquid Biopsy
Exact Sciences Co. (NASDAQ: EXAS) had its price target lowered by analysts at Piper Sandler from $85.00 to $75.00. They now have an "overweight" rating on the stock.
Exact Sciences Co. (NASDAQ: EXAS) had its price target raised by analysts at Jefferies Financial Group Inc. from $84.00 to $85.00. They now have a "buy" rating on the stock.
Exact Sciences Co. (NASDAQ: EXAS) had its price target lowered by analysts at Citigroup Inc. from $80.00 to $75.00. They now have a "buy" rating on the stock.
Show more
Live Event: Join our next subscriber-only event: "The Data Driven Investor"
Register for our next upcoming LIVE training session, which will be hosted on Tuesday April 24th at 08:00 PM EST (New York Time).
Get your questions answered during the Q & A session.
For any support questions, contact our team: support@newsquantified.com